Favorable PCAC votes for BPC-157, KPV, and TB-500 built momentum for a federal route that places patient-specific peptide compounding inside licensed pharmacy oversight.
The July 2026 PCAC meeting turned the Section 503A Bulks List into the center of the peptide world.
BPC-157, KPV, and TB-500 all received favorable committee recommendations on July 23. Each result moved the same big idea forward: a clearer federal route for peptide compounding through licensed pharmacies.
What is the Section 503A Bulks List?
The Section 503A Bulks List names bulk drug substances that can be used in certain patient-specific compounded prescriptions when the federal statutory conditions are met.
That matters because many compounded prescriptions begin with a bulk active ingredient. The list tells 503A pharmacies which nominated substances have a federal route for that use.
What role does PCAC play?
The Pharmacy Compounding Advisory Committee reviews the scientific and compounding record, hears public testimony, and votes on recommendations to FDA.
At the July 23–24 meeting, PCAC considered 14 questions across seven peptides. Each peptide had a separate free-base and acetate question.
The favorable July 23 peptide votes
- BPC-157 free base: 8 yes / 6 no / 1 abstention
- BPC-157 acetate: 8 yes / 6 no / 1 abstention
- KPV: favorable recommendation
- TB-500: 8 yes / 6 no / 1 abstention
Three peptides, four favorable questions, and a major shift in momentum for the 503A Bulks List.
Why Category 1 became part of the debate
Category 1 gives nominated bulk drug substances an interim route while FDA completes its evaluation. During the TB-500 hearing, Dr. Alex Tatem argued that restoring Category 1 status would move existing demand away from grey-market research products and into regulated compounding.
That argument landed because it addressed the market as it exists today. Patients are already seeking peptides. A 503A route brings that demand into licensed pharmacies, patient-specific prescriptions, and documented quality systems.
Read Dr. Alex Tatem's full TB-500 PCAC case.
The full July 2026 PCAC peptide slate
The meeting covers seven peptides in free-base and acetate forms:
- BPC-157
- KPV
- TB-500
- MOTS-c
- Emideltide, also known as DSIP
- Epitalon
- Semax
Follow every result on Rebody's live PCAC peptide vote tracker. The tracker includes direct links to the official July 23 and July 24 FDA webcasts.
What the PCAC wins mean now
The favorable recommendations put BPC-157, KPV, and TB-500 in a stronger position as FDA moves through the federal list process. They also established a public record built on real-world use, compounding-quality submissions, and direct committee votes.
For the full Day 1 story, read BPC-157, KPV, and TB-500 Win Favorable PCAC Votes.
503A and PCAC FAQ
What is the 503A Bulks List?
It is the federal list of bulk drug substances that may be used in certain patient-specific compounded prescriptions when the Section 503A conditions are met.
What does PCAC do?
PCAC reviews pharmacy-compounding questions and votes on recommendations to FDA.
Which peptides received favorable votes on July 23?
BPC-157, KPV, and TB-500 received favorable PCAC recommendations.